All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
In order to improve prevention of Multiple Myeloma (MM), identifying risk factors is essential. Currently, the most established risk factors are non-modifiable factors such as old age, male gender, African descent, and a family history of hematologic malignancies. Although a few epidemiologic studies have shown a positive association between obesity and MM risk, there is still little known about the impact of body mass index (BMI) in earlier and later life and the associated risk for MM.
Catherine R. Marinac from the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, US, and colleagues, analyzed data from three large prospective cohorts to assess whether changes in BMI or physical activity, affect the risk of developing MM. The results of this study were published in the British Journal of Cancer in April 2018.
(MET-h was used to assess physical activity and is a measure of total metabolic equivalent hours of all activity including walking, per week)
This study, therefore, confirms a significant association between high BMI in early and late adulthood and an increased risk of developing MM. This finding ties in with previous research showing that obesity is a risk factor for progression from monoclonal gammopathy of undetermined significance (MGUS) to MM – read here. Obesity is, therefore, a modifiable factor for patients with MM, with well-managed weight control part of a valid strategy for reducing the risk of developing MM in patients with MGUS.
References
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?